SCT and breast carcinoma: Others [28] have reported a change in GBM cell line proliferation in response to CTR stimulation and this has also been reported for a breast cancer cell line [50, 51], we therefore assessed whether activation (using both hCT and sCT) or blockade (using the antagonist sCT(8–32)) would alter metabolism in the SB2b cell line.